Syntara

Syntara EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Syntara (SNT.AX) as of Oct 31, 2026 is -3.20. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -2.36 — a change of 35.44% (lower).

EV/EBIT

-3.20

YoY

35.44%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Syntara is 2026 -3.20 . EV/EBIT (Enterprise Value to EBIT) of Syntara was 2025 -2.36 . It decreases by 35.44% lower compared to the previous year.

The Syntara EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-2.70 AUD
Jan 1, 2020
-3.29 AUD
Jan 1, 2021
-2.30 AUD
Jan 1, 2022
-2.63 AUD
Jan 1, 2023
-2.80 AUD
Jan 1, 2024
-3.72 AUD
Jan 1, 2025
-2.36 AUD
Jan 1, 2026
-3.20 AUD
The Syntara EV/EBIT history
YEAREV/EBITYoY
-3.20+35.44%
-2.36-36.51%
-3.72+32.92%
-2.80+6.12%
-2.63+14.79%
-2.30-30.26%
-3.29+22.10%
-2.70-136.02%
7.48-353.80%
-2.95+5.74%
-2.79-186.14%
3.24-320.71%
-1.47+537.68%
-0.23-68.92%
-0.74+60.87%
-0.46+64.29%
-0.28-15.15%
-0.33+120.00%
-0.15-70.00%
-0.50—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Syntara Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Syntara's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Syntara's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Syntara's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Syntara grows earnings faster than its peers.

Syntara Stock analysis

What does Syntara do? Syntara Ltd generates revenue through the development and commercialization of pharmaceutical products targeting blood-related cancers and fibrotic diseases. Its lead candidate PXS-5505 is designed for myelofibrosis, a bone marrow cancer causing blood cell loss, while PXS-4728 serves as an SSAO/MAOB inhibitor for sleep disorders and neurodegenerative diseases. The company also markets Bronchitol for cystic fibrosis and Aridol as a lung function test, focusing on respiratory and fibrotic conditions. These products are developed through Syntara's drug discovery engine centered on amine oxidase inhibitors and pan-LOX inhibitors. The company's primary customers are healthcare providers and patients seeking treatments for myelofibrosis, fibrotic diseases, and respiratory conditions. Syntara's drug candidates target specific medical segments including oncology for blood cancers, neurology for Parkinson's disease progression, and respiratory care for cystic fibrosis. The firm advances its pipeline through clinical-stage development, leveraging its expertise in amine oxidase inhibitors to address unmet medical needs in these therapeutic areas. Syntara Limited, formerly Pharmaxis Ltd, operates as a clinical-stage drug development company with a focus on blood-related cancers. Its product portfolio includes PXS-5505 for myelofibrosis, PXS-4728 for neurodegenerative diseases, Bronchitol for cystic fibrosis, and Aridol for lung function testing. The company's revenue streams derive from the advancement of these drug candidates through clinical trials and potential future commercialization, with no indication of current commercial sales in the provided description. Syntara is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Syntara stock

EV/EBIT (Enterprise Value to EBIT) of Syntara is -3.20 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Syntara changed from -2.36 to -3.20, representing a 35.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Syntara since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Syntara with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Syntara

All Key Metrics — Syntara